Union Acquisition Corp. II
LATNU
NASDAQ Global Select10.96
USD
- -
- -
CIK
0001766146
Return %
Stock
S&P500
1Y
- -
26.53
3Y
- -
76.60
5Y
9.49
80.11
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Kyle P. Bransfield
- Sector
- Financial Services
- Industry
- Shell Companies
- Address
- 509 Madison Avenue New York City NY United States of America 10022
- IPO Date
- Oct 18, 2019
- CIK
- 0001766146
- Website
- unionacquisitiongroup.com
- Similar Companies
- Business
- Union Acquisition Corp. II (NASDAQ: LATNU) operates as a blank check company, or special purpose acquisition company (SPAC), incorporated in the Cayman Islands to effect a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or similar business combination with one or more target businesses, with a primary focus on opportunities in Latin America; its units comprise one Class A ordinary share and one-half of one redeemable warrant. The company, founded in 2019 and headquartered in Miami, Florida, completed its initial public offering of 20 million units at $10.00 each in October 2019, raising $200 million before underwriters' discounts. In September 2021, Union Acquisition Corp. II completed a $1.1 billion business combination with Procaps Group, S.A., a leading integrated Latin American healthcare and pharmaceutical company specializing in prescription drugs, over-the-counter products, and nutraceuticals; post-merger, Procaps ordinary shares and warrants began trading on Nasdaq under the symbols PROC and PROCW, providing approximately $160 million in gross proceeds to support organic growth, capacity expansion, R&D, and inorganic M&A roll-up strategies across 13 countries with product reach in 50 markets. Procaps, the surviving entity, recently received a Nasdaq delisting notice in February 2025 for failure to file periodic financial reports in compliance with Listing Rules 5250(c)(1) and 5250(c)(2), with its shares transitioning to the OTC Expert Market effective February 4, 2025; the company faces ongoing cash flow pressures, leadership transitions including Ruben Minski stepping down as Executive Chairman in 2024 while remaining on the board and the appointment of José Minski as successor alongside new CEO José Antonio Vieira, and is developing a long-term restructuring plan with financial advisors.